Midlife Blood Biomarkers Reveal Alzheimer Risk Before Symptoms Appear
Scientists have long suspected that Alzheimer’s disease begins long before memory loss becomes evident. New data now confirm that certain blood‑based biomarkers can be detected in people in their forties and fifties, offering a window into the disease’s silent phase. The cohort study screened thousands of middle‑aged volunteers for phosphorylated tau and amyloid‑beta concentrations, proteins that accumulate in the brain during Alzheimer’s progression. Participants with elevated levels showed modest deficits on standardized neuropsychological tests, even after researchers accounted for demographic variables, body weight, renal health and genetic risk factors such as the APOE allele. Notably, the correlation between biomarker elevation and cognitive decline was most pronounced in women, Black respondents and carriers of the APOE4 variant. The research underscores the potential of low‑cost blood assays to serve as an early warning system, though the authors stress the need for larger, longitudinal trials to establish clinical utility.